Bayer Gamunex approved
Executive Summary
Bayer Gamunex human immune globulin I.V. approved by FDA Aug. 27 for primary humoral immunodeficiency and idiopathic thrombocytopenic purpura. The biologic is the first new IGIV product submitted to FDA in more than a decade. In its announcement of the approval, Bayer refers to Gamunex as a "differentiated, next-generation" product and notes that "not all IGIVs are the same." FDA issued a statement in September advising healthcare providers to disregard manufacturer letters suggesting superiority of certain IGIV products over others (1"The Pink Sheet" Sep. 2, 2002, p. 13)...
You may also be interested in...
IGIV Manufacturer Letters Should Be Ignored During FDA Review, Agency Says
Prescriber letters sent by immune globulin intravenous manufacturers asserting superiority over other IGIV products should be disregarded while FDA completes its safety review of thrombotic events, the agency said
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.